These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 21601982)

  • 1. The contemporary concept of significant versus insignificant prostate cancer.
    Ploussard G; Epstein JI; Montironi R; Carroll PR; Wirth M; Grimm MO; Bjartell AS; Montorsi F; Freedland SJ; Erbersdobler A; van der Kwast TH
    Eur Urol; 2011 Aug; 60(2):291-303. PubMed ID: 21601982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
    Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
    Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-risk prostate cancer: from definition to contemporary management.
    Bastian PJ; Boorjian SA; Bossi A; Briganti A; Heidenreich A; Freedland SJ; Montorsi F; Roach M; Schröder F; van Poppel H; Stief CG; Stephenson AJ; Zelefsky MJ
    Eur Urol; 2012 Jun; 61(6):1096-106. PubMed ID: 22386839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men.
    Chun FK; Haese A; Ahyai SA; Walz J; Suardi N; Capitanio U; Graefen M; Erbersdobler A; Huland H; Karakiewicz PI
    Cancer; 2008 Aug; 113(4):701-9. PubMed ID: 18553365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating localized prostate cancer and identifying candidates for focal therapy.
    Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
    Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is a single focus of low-grade prostate cancer diagnosed on saturation biopsy predictive of clinically insignificant cancer?
    Pepe P; Fraggetta F; Galia A; Candiano G; Grasso G; Aragona F
    Urol Int; 2010; 84(4):440-4. PubMed ID: 20234121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
    Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
    BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ-confined disease.
    Miyake H; Sakai I; Harada K; Hara I; Eto H
    Int J Urol; 2005 Mar; 12(3):270-4. PubMed ID: 15828954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contemporary grading for prostate cancer: implications for patient care.
    Brimo F; Montironi R; Egevad L; Erbersdobler A; Lin DW; Nelson JB; Rubin MA; van der Kwast T; Amin M; Epstein JI
    Eur Urol; 2013 May; 63(5):892-901. PubMed ID: 23092544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of Gleason pattern 4/5 prostate cancer on prostatectomy specimens: can high grade tumor be predicted preoperatively?
    Rubin MA; Mucci NR; Manley S; Sanda M; Cushenberry E; Strawderman M; Montie JE; Bassily NH
    J Urol; 2001 Jan; 165(1):114-8. PubMed ID: 11125378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features.
    Boccon-Gibod LM; Dumonceau O; Toublanc M; Ravery V; Boccon-Gibod LA
    Eur Urol; 2005 Dec; 48(6):895-9. PubMed ID: 16125298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between tumor volume and the number of positive cores in men undergoing multisite extended biopsy: implication for expectant management.
    Ochiai A; Troncoso P; Chen ME; Lloreta J; Babaian RJ
    J Urol; 2005 Dec; 174(6):2164-8, discussion 2168. PubMed ID: 16280756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy.
    Cheng L; Koch MO; Juliar BE; Daggy JK; Foster RS; Bihrle R; Gardner TA
    J Clin Oncol; 2005 May; 23(13):2911-7. PubMed ID: 15860849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the tertiary Gleason pattern influence the PSA progression-free interval after retropubic radical prostatectomy for organ-confined prostate cancer?
    van Oort IM; Schout BM; Kiemeney LA; Hulsbergen CA; Witjes JA
    Eur Urol; 2005 Oct; 48(4):572-6. PubMed ID: 16046051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The percentage of core involved by cancer is the best predictor of insignificant prostate cancer, according to an updated definition (tumor volume up to 2.5 cm3): analysis of a cohort of 210 consecutive patients with low-risk disease.
    Antonelli A; Vismara Fugini A; Tardanico R; Giovanessi L; Zambolin T; Simeone C
    Urology; 2014 Jan; 83(1):28-32. PubMed ID: 24269219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of pathological prostate cancer characteristics in men with favorable biopsy features on predominantly sextant biopsy.
    Chun FK; Suardi N; Capitanio U; Jeldres C; Ahyai S; Graefen M; Haese A; Steuber T; Erbersdobler A; Montorsi F; Huland H; Karakiewicz PI
    Eur Urol; 2009 Mar; 55(3):617-28-6. PubMed ID: 18499335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis.
    Cupp MR; Bostwick DG; Myers RP; Oesterling JE
    J Urol; 1995 May; 153(5):1543-8. PubMed ID: 7714976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate biopsy: who, how and when. An update.
    Djavan B; Milani S; Remzi M
    Can J Urol; 2005 Feb; 12 Suppl 1():44-8; discussion 99-100. PubMed ID: 15780165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a difference in outcome after radical prostatectomy between patients with biopsy Gleason sums 4, 5, and 6? Results from the SEARCH database.
    Freedland SJ; Amling CL; Terris MK; Presti JC; Aronson WJ; Elashoff D; Kane CJ;
    Prostate Cancer Prostatic Dis; 2003; 6(3):261-5. PubMed ID: 12970733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A nomogram for predicting low-volume/low-grade prostate cancer: a tool in selecting patients for active surveillance.
    Nakanishi H; Wang X; Ochiai A; Trpkov K; Yilmaz A; Donnelly JB; Davis JW; Troncoso P; Babaian RJ
    Cancer; 2007 Dec; 110(11):2441-7. PubMed ID: 17932909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.